Ignite Creation Date:
2024-05-06 @ 3:45 AM
Last Modification Date:
2024-10-26 @ 11:38 AM
Study NCT ID:
NCT02364362
Status:
COMPLETED
Last Update Posted:
2019-01-18
First Post:
2015-01-19
Brief Title:
A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit VEGFR2 PDGFR VEGFR3 Flt1 and Flt3 Phase I study has shown that the toxicity is manageable
This study assessed the safety and maximum tolerated dose of continuous daily treatment with Famitinib plus docetaxel 60 mgm2 every 3 weeks in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC to determine the recommended dose for the Phase II trial
This study assessed the safety and maximum tolerated dose of continuous daily treatment with Famitinib plus docetaxel 60 mgm2 every 3 weeks in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC to determine the recommended dose for the Phase II trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None